<DOC>
	<DOC>NCT02907177</DOC>
	<brief_summary>This clinical study compares the efficacy, safety, and tolerability of therapy with ponesimod vs placebo in subjects with active RMS who are treated with DMF (Tecfidera®).</brief_summary>
	<brief_title>Clinical Study to Compare the Efficacy and Safety of Ponesimod to Placebo in Subjects With Active Relapsing Multiple Sclerosis Who Are Treated With Dimethyl Fumarate (Tecfidera®)</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Dimethyl Fumarate</mesh_term>
	<criteria>Signed informed consent prior to initiation of any studymandated procedure. Women of childbearing potential must have a negative pregnancy test and use reliable methods of contraception Presenting with a diagnosis of MS as defined by the revised (2010) McDonald Diagnostic Criteria for MS with relapsing course from onset (i.e., relapsingremitting multiple sclerosis (RRMS), or secondary progressive multiple sclerosis (SPMS) with superimposed relapses). Ongoing treatment with DMF for at least 6 months prior to screening; Active disease in the 12 months prior to screening and after at least 3 months of DMF treatment Ambulatory and with an EDSS score between 0 and 6.0 (inclusive). Lactating or pregnant women and women intending to become pregnant during the study. Presenting with a diagnosis of MS with progressive course from onset (i.e., primary progressive MS or progressive relapsing MS). Evidence of a relapse of MS with onset within 30 days prior to baseline EDSS assessment. Any circumstances or conditions, which, in the opinion of the investigator, may affect full participation in the study or compliance with the protocol.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>